Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved tislelizumab-jsgr (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death ligand-1 (PD-L1) (≥1).
The additional indication is based on results from BeiGene’s RATIONALE-306 (ClinicalTrials.gov.